KPTI · Karyopharm Therapeutics Inc. · Financials
$0.48
0.00 (-0.44%)
At close · Oct 27
Return incl. dividend (before tax)
Q2 2026 earnings call transcript
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current business plan and current capital resources, combined with the uncertainty regarding the availability of additional funding or other strategic alternatives and considering our debt service obligations and financial covenant to maintain minimum liquidity, we have concluded that there is substantial doubt regarding our ability to continue as a going concern within one year after the date the accompanying condensed consolidated financial statements are issued.”View the 10-Q filed Aug 13, 2026
Market Cap
$10.93M
Shares
22.68M
Volume · Oct 27
996.52K
Avg daily vol (3M)
1.95M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$146.07M
+0.6%
FY2025
Net Income
-$196.04M
-156.5%
FY2025
Operating Margin
-62.1%
+20.1pp
FY2025
Diluted EPS
-$17.93
-28.1%
FY2025
Operating Cash Flow
-$75.37M
+40.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $130M – $150M | $146.62M | $146.07MG | $145.24MG | $146.03MG | $157.07MG | $209.82M | $108.09M | $40.89M | $30.34M | $1.61M | $154K | $250K | $229K | $387K | $634K | $152K | — | — | |
| — | $120.97M | $125.62M | $143.23M | $138.75M | $148.66M | $160.84M | $150.81M | $122.34M | $161.37M | $107.27M | $86.94M | $97.74M | $60.13M | $28.45M | $14.1M | $8.62M | — | — | |
| — | — | — | — | — | — | — | — | — | $48.85M | $24.87M | $23.95M | $21.58M | $15.95M | $5.89M | $2.43M | $1.84M | — | — | |
| — | $101.98M | $105.21M | $115.44M | $131.88M | $145.4M | $143.85M | $126.42M | $105.42M | $48.85M | $24.87M | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | $974K | $735K | $713K | $717K | $634K | $323K | $144K | $122K | $83K | — | — | |
| — | $228.97M | $236.77M | $264.68M | $275.57M | $299.28M | $308.09M | $279.94M | $230.17M | $210.22M | $132.14M | $110.89M | $119.33M | $76.08M | $34.34M | $16.52M | $10.46M | — | — | |
| — | — | — | — | — | — | $3.4M | $2.71M | $2.41M | — | — | — | — | — | — | — | — | — | — | |
| — | -$82.35M | -$90.71M | -$119.44M | -$129.54M | -$142.2M | -$98.27M | -$171.85M | -$189.28M | -$179.88M | -$130.54M | -$110.73M | -$119.08M | -$75.85M | -$33.95M | -$15.89M | -$10.31M | — | — | |
| — | — | -62.1% | -82.24% | -88.71% | -90.53% | -46.84% | -159% | -462.85% | -592.97% | -8133.21% | -71903.9% | -47630.4% | -33120.52% | -8772.61% | -2506.31% | -6783.55% | — | — | |
| — | — | — | — | — | — | — | — | -$188.3M | -$179.15M | -$129.83M | -$110.02M | -$118.44M | -$75.52M | -$33.81M | -$15.77M | -$10.23M | — | — | |
| — | $49.32M | $45.85M | $37.42M | $23.82M | $25M | $26.05M | $27.14M | $15.65M | $2.49M | — | — | — | $1000 | — | — | — | — | — | |
| — | $2.39M | $2.77M | $7.4M | $10.94M | $2.36M | $582K | $2.82M | $5.42M | $4.03M | $1.7M | $1.28M | $897K | $97K | $3000 | $2000 | — | — | — | |
| — | -$142.42M | -$105.29M | $43.08M | -$13.24M | -$22.72M | -$25.55M | -$24.11M | -$10.28M | $1.5M | $1.62M | $1.29M | $895K | $69K | $3000 | $2000 | — | — | — | |
| — | -$224.77M | -$196M | -$76.37M | -$142.78M | -$164.92M | -$123.82M | -$195.96M | -$199.55M | -$178.38M | -$128.92M | -$109.44M | -$118.18M | -$75.78M | — | — | — | — | — | |
| — | -$32K | $43K | $57K | $323K | $369K | $268K | $309K | $40K | $26K | $63K | $139K | -$118.09M | -$75.78M | -$33.95M | -$15.89M | — | — | — | |
| — | -$224.74M | -$196.04M | -$76.42M | -$143.1M | -$165.29M | -$124.09M | -$196.27M | -$199.59M | -$178.41M | -$128.98M | -$109.58M | -$118.18M | -$75.78M | -$33.95M | -$15.89M | — | — | — | |
| — | — | -134.21% | -52.62% | -97.99% | -105.23% | -59.14% | -181.59% | -488.08% | -588.1% | -8036.39% | -71153.9% | -47272.4% | -33090.39% | -8771.83% | -2505.99% | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | -$75.78M | -$33.95M | -$15.89M | -$10.31M | -$2.24M | -$179K | |
| — | -$224.45M | -$195.61M | -$76.62M | -$142.62M | -$166.12M | -$124.42M | -$195.72M | -$199.38M | -$178.43M | -$128.93M | -$109.57M | -$118.43M | -$75.81M | -$33.95M | -$15.89M | — | — | — | |
| USD/shares | — | -$14.18 | -$17.93 | -$9.41 | -$18.79 | -$30.30 | -$24.75 | -$40.80 | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | — | -$14.40 | -$17.93 | -$14.00 | -$18.79 | -$30.30 | -$24.75 | -$40.80 | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | — | 10.94K | 8125 | 7616 | 5458.0667 | 5.01M | 4.8M | 4.13M | 3785.3333 | 3.06M | 2.5M | 2.37M | 2.08M | 404.51K | 118.35K | 66.94K | — | — |
| shares | — | — | 10.94K | 8455 | 7616 | 5458.0667 | 5.01M | 4.8M | 4.13M | 3785.3333 | 3.06M | 2.5M | 2.37M | 2.08M | 404.51K | 118.35K | 66.94K | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current operating lease liabilities | 2026-06-30 | USD 1,068,000 | 10-Q filed 2026-08-13 |
| Current portion of secured debt | 2026-06-30 | USD 40,307,000 | 10-Q filed 2026-08-13 |
| Noncurrent operating lease liabilities | 2026-06-30 | USD 5,183,000 | 10-Q filed 2026-08-13 |
| Noncurrent secured debt | 2026-06-30 | USD 85,047,000 | 10-Q filed 2026-08-13 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.78×
EV/EBIT
—
Peer median 5.37×
P/E (TTM)
—
Peer median 3.81×
Peer medians compare against the 242 similar-size Biotechnology companies (of 565 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Product | $114,857,000 | $112,806,000 | $112,011,000 | $120,445,000 | $98,436,000 | $76,210,000 | $30,540,000 | $0 |
| License and Other | $31,210,000 | $32,431,000 | $34,022,000 | $36,629,000 | $111,383,000 | $31,875,000 | $10,353,000 | $30,336,000 |
| License And Service | $3,500,000 | — | — | — | — | — | — | — |
Key facts
CIK
1503802
CUSIP
48576U205
13F (30d)
10 filings
10 filers
Visit website
Investor relations